CORRECTION -- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
Propanc Biopharma's board approved a 1-for-10 reverse stock split, effective before market open on October 26, 2026, reducing outstanding shares from roughly 10.3 million to about 1.0 million. The company said the split is intended to restore compliance with Nasdaq's continued listing standards and the $1.00 minimum bid price requirement while supporting future growth plans.
Key figures
- New cusip
- 74346N883
- Effective date
- October 26, 2026
- Reverse split ratio
- 1-for-10
- Shares outstanding pre split
- approximately 10,331,116 shares
- Shares outstanding post split
- approximately 1,033,112 shares
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.